Literature DB >> 1294747

Septic arthritis in patients with acquired immunodeficiency syndrome with human immunodeficiency virus infection.

J Rivera1, I Monteagudo, J Lopez-Longo, A Sanchez-Atrio.   

Abstract

We have evaluated the presence and characteristics of septic arthritis in intravenous (iv) drug users with human immunodeficiency virus (HIV) infection. Sixteen patients with both HIV infection and septic arthritis were studied and compared with 5 patients with septic arthritis but no HIV infection. Clinical profile, laboratory findings at the time of onset, localization, causative organisms, mean hospitalization time and presence of complications were the same in HIV positive and HIV negative patients. Staphylococcus aureus was the most commonly isolated organism in both groups. We conclude that septic arthritis in HIV infected iv drug users is not uncommon, it is produced by the same organisms and presents similar characteristics to the ones found in iv drug users without HIV infection. Therefore, the presence of HIV infection does not appear to modify the characteristics of septic arthritis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1294747

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Osteoarticular and muscle infectious lesions in patients with the human immunodeficiency virus.

Authors:  J Belzunegui; C Gonzalez; L Lopez; I Plazaola; O Maiz; M Figueroa
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

Review 2.  Pyogenic arthritis caused by streptococcus equisimilis (group-C streptococcus) in a patient with AIDS.

Authors:  S Steinfeld; C Galle; M Struelens; Y De Gheldre; C M Farber; T Appelboom; J P Van Vooren
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

Review 3.  Does intravenous immune globulin have a role in HIV-infected patients?

Authors:  P L Yap
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  Candida arthritis in an immunocompetent patient without predisposing factors.

Authors:  J M Calvo Romero; J L Alvarez Vega; J M Salazar Vallinas; R Ortega Alberdi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.